User menu

Predictors of disability worsening in clinically isolated syndrome.

Bibliographic reference Jokubaitis, Vilija G ; Spelman, Tim ; Kalincik, Tomas ; Izquierdo, Guillermo ; Grand'Maison, François ; et. al. Predictors of disability worsening in clinically isolated syndrome.. In: Annals of Clinical and Translational Neurology, Vol. 2, no.5, p. 479-491 (2015)
Permanent URL http://hdl.handle.net/2078.1/171998
  1. Kappos L., Traboulsee A., Constantinescu C., Eralinna J. -P., Forrestal F., Jongen P., Pollard J., Sandberg-Wollheim M., Sindic C., Stubinski B., Uitdehaag B., Li D., Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS, 10.1212/01.wnl.0000237994.95410.ce
  2. Polman Chris H., O'Connor Paul W., Havrdova Eva, Hutchinson Michael, Kappos Ludwig, Miller David H., Phillips J. Theodore, Lublin Fred D., Giovannoni Gavin, Wajgt Andrzej, Toal Martin, Lynn Frances, Panzara Michael A., Sandrock Alfred W., A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis, 10.1056/nejmoa044397
  3. Rudick Richard A., Stuart William H., Calabresi Peter A., Confavreux Christian, Galetta Steven L., Radue Ernst-Wilhelm, Lublin Fred D., Weinstock-Guttman Bianca, Wynn Daniel R., Lynn Frances, Panzara Michael A., Sandrock Alfred W., Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis, 10.1056/nejmoa044396
  4. Kurtzke J. F., Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS), 10.1212/wnl.33.11.1444
  5. Ebers George C, Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis, 10.1016/s0140-6736(98)03334-0
  6. Jacobs Lawrence, Rudick Richard, Simon Jack, Extended observations on MS patients treated with IM interferon-β1a (Avonex™): implications for modern MS trials and therapeutics, 10.1016/s0165-5728(00)00232-0
  7. Noseworthy J. H., O'Brien P., Erickson B. J., Lee D., Sneve D., Ebers G. C., Rice G.P.A., Auty A., Hader W. J., Kirk A., Duquette P., Carter J., Francis G., Metz L., Shuster E., , The Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosis, 10.1212/wnl.51.5.1342
  8. Rudick R. A., Goodkin D. E., Jacobs L. D., Cookfair D. L., Herndon R. M., Richert J. R., Salazar A. M., Fischer J. S., Granger C. V., Simon J. H., Alam J. J., Simonian N. A., Campion M. K., Bartoszak D. M., Bourdette D. N., Braiman J., Brownscheidle C. M., Coats M. E., Cohan S. L., Dougherty D. S., Kinkel R. P., Mass M. K., Munschauer F. E., Priore R. L., Pullicino P. M., Scherokman B. J., Weistock-Guttman B., Whitham R. H., , Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis, 10.1212/wnl.49.2.358
  9. Wolinsky Jerry S., Narayana Ponnada A., O'Connor Paul, Coyle Patricia K., Ford Corey, Johnson Kenneth, Miller Aaron, Pardo Lillian, Kadosh Shaul, Ladkani David, , Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial, 10.1002/ana.21079
  10. , Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial, 10.1212/wnl.45.7.1277
  11. Liu C., Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts, 10.1136/jnnp.68.4.450
  12. Trojano M., Pellegrini F., Paolicelli D., Fuiani A., Zimatore G.B., Tortorella C., Simone I.L., Patti F., Ghezzi A., Zipoli V., Rossi P., Pozzilli C., Salemi G., Lugaresi A., Bergamaschi R., Millefiorini E., Clerico M., Lus G., Vianello M., Avolio C., Cavalla P., Lepore V., Livrea P., Comi G., Amato M.P., , Real-life impact of early interferonβ therapy in relapsing multiple sclerosis : Early IFNβ Treatment in RRMS, 10.1002/ana.21757
  13. MSBase http://www.msbase.org
  14. Butzkueven H, Chapman J, Cristiano E, Grand’Maison F, Hoffmann M, Izquierdo G, Jolley D, Kappos L, Leist T, Pöhlau D, Rivera V, Trojano M, Verheul F, Malkowski J-P, MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis, 10.1177/1352458506070775
  15. Meyniel Claire, Spelman Timothy, Jokubaitis Vilija G., Trojano Maria, Izquierdo Guillermo, Grand’Maison François, Oreja-Guevara Celia, Boz Cavit, Lugaresi Alessandra, Girard Marc, Grammond Pierre, Iuliano Gerardo, Fiol Marcela, Cabrera-Gomez Jose Antonio, Fernandez-Bolanos Ricardo, Giuliani Giorgio, Lechner-Scott Jeannette, Cristiano Edgardo, Herbert Joseph, Petkovska-Boskova Tatjana, Bergamaschi Roberto, van Pesch Vincent, Moore Fraser, Vella Norbert, Slee Mark, Santiago Vetere, Barnett Michael, Havrdova Eva, Young Carolyn, Sirbu Carmen-Adella, Tanner Mary, Rutherford Michelle, Butzkueven Helmut, , Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome, 10.1371/journal.pone.0038661
  16. Comi Giancarlo, Filippi Massimo, Barkhof Frederik, Durelli Luca, Edan Gilles, Fernández Oscar, Hartung Hans-Peter, Seeldrayers Pierrette, Sørensen Per Soelberg, Rovaris Marco, Martinelli Vittorio, Hommes Otto R, Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study, 10.1016/s0140-6736(00)04725-5
  17. Confavreux C., Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process, 10.1093/brain/awg081
  18. D’Alessandro Roberto, Vignatelli Luca, Lugaresi Alessandra, Baldin Elisa, Granella Franco, Tola Maria Rosaria, Malagù Susanna, Motti Luisa, Neri Walter, Galeotti Massimo, Santangelo Mario, Fiorani Laila, Montanari Enrico, Scandellari Cinzia, Benedetti Maria Donata, Leone Maurizio, Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study, 10.1007/s00415-013-6838-x
  19. Damasceno Alfredo, Von Glehn Felipe, Brandão Carlos Otávio, Damasceno Benito Pereira, Cendes Fernando, Prognostic indicators for long-term disability in multiple sclerosis patients, 10.1016/j.jns.2012.09.020
  20. Healy Brian C., Engler David, Gholipour Taha, Weiner Howard, Bakshi Rohit, Chitnis Tanuja, Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis, 10.1016/j.jns.2010.12.024
  21. Runmarker Björn, Andersen Oluf, Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up, 10.1093/brain/116.1.117
  22. Shirani Afsaneh, Zhao Yinshan, Karim Mohammad Ehsanul, Evans Charity, Kingwell Elaine, van der Kop Mia L., Oger Joel, Gustafson Paul, Petkau John, Tremlett Helen, Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis, 10.1001/jama.2012.7625
  23. Trojano M, Avolio C, Manzari C, Calo A, De Robertis F, Serio G, Livrea P, Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events., 10.1136/jnnp.58.3.300
  24. Jacobs Lawrence D., Cookfair Diane L., Rudick Richard A., Herndon Robert M., Richert John R., Salazar Andres M., Fischer Jill S., Goodkin Donald E., Granger Carl V., Simon Jack H., Alam John J., Bartoszak David M., Bourdette Dennis N., Braiman Jonathan, Brownscheidle Carol M., Coats Michael E., Cohan Stanley L., Dougherty David S., Kinkel Revere P., Mass Michele K., Munschauer Frederick E., Priore Roger L., Pullicino Patrick M., Scherokman Barbara J., Weinstock-Guttman Bianca, Whitham Ruth H., , Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis, 10.1002/ana.410390304
  25. Ebers G. C., Traboulsee A., Li D., Langdon D., Reder A. T., Goodin D. S., Bogumil T., Beckmann K., Wolf C., Konieczny A., , Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial, 10.1136/jnnp.2009.204123
  26. Uitdehaag Bernard, Constantinescu Cris, Cornelisse Peter, Jeffery Douglas, Kappos Ludwig, Li David, Sandberg-Wollheim Magnhild, Traboulsee Anthony, Verdun Elisabetta, Rivera Victor, Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study, 10.1177/1756285610391693
  27. Tremlett H., Yousefi M., Devonshire V., Rieckmann P., Zhao Y., , Impact of multiple sclerosis relapses on progression diminishes with time, 10.1212/wnl.0b013e3181c1e44f
  28. Brex Peter A., Ciccarelli Olga, O'Riordan Jonathon I., Sailer Michael, Thompson Alan J., Miller David H., A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis, 10.1056/nejmoa011341
  29. Fisniku L. K., Brex P. A., Altmann D. R., Miszkiel K. A., Benton C. E., Lanyon R., Thompson A. J., Miller D. H., Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis, 10.1093/brain/awm329
  30. O'Riordan J., The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up, 10.1093/brain/121.3.495
  31. Tintore M., Rovira A., Rio J., Nos C., Grive E., Tellez N., Pelayo R., Comabella M., Sastre-Garriga J., Montalban X., Baseline MRI predicts future attacks and disability in clinically isolated syndromes, 10.1212/01.wnl.0000237354.10144.ec
  32. Comi Giancarlo, Martinelli Vittorio, Rodegher Mariaemma, Moiola Lucia, Leocani Letizia, Bajenaru Ovidiu, Carra Adriana, Elovaara Irina, Fazekas Franz, Hartung Hans-Peter, Hillert Jan, King John, Komoly Samuel, Lubetzki Catherine, Montalban Xavier, Myhr Kjell-Morten, Preziosa Paolo, Ravnborg Mads, Rieckmann Peter, Rocca Maria A, Wynn Daniel, Young Carolyn, Filippi Massimo, Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome, 10.1177/1352458512469695
  33. Kappos L., Polman C. H., Freedman M. S., Edan G., Hartung H. P., Miller D. H., Montalban X., Barkhof F., Bauer L., Jakobs P., Pohl C., Sandbrink R., , Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes, 10.1212/01.wnl.0000237641.33768.8d
  34. , IM interferon  -1a delays definite multiple sclerosis 5 years after a first demyelinating event, 10.1212/01.wnl.0000200778.65597.ae
  35. Kappos Ludwig, Freedman Mark S, Polman Chris H, Edan Gilles, Hartung Hans-Peter, Miller David H, Montalbán Xavier, Barkhof Frederik, Radü Ernst-Wilhelm, Bauer Lars, Dahms Susanne, Lanius Vivian, Pohl Christoph, Sandbrink Rupert, Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study, 10.1016/s0140-6736(07)61194-5
  36. Kappos Ludwig, Freedman Mark S, Polman Chris H, Edan Gilles, Hartung Hans-Peter, Miller David H, Montalbán Xavier, Barkhof Frederik, Radü Ernst-Wilhelm, Metzig Carola, Bauer Lars, Lanius Vivian, Sandbrink Rupert, Pohl Christoph, Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial, 10.1016/s1474-4422(09)70237-6
  37. Trojano Maria, Paolicelli Damiano, Tortorella Carla, Iaffaldano Piero, Lucchese Guglielmo, Di Renzo Vita, D’Onghia Mariangela, Natural History of Multiple Sclerosis: Have Available Therapies Impacted Long-Term Prognosis?, 10.1016/j.ncl.2010.12.008
  38. Brown M. G., Kirby S., Skedgel C., Fisk J. D., Murray T. J., Bhan V., Sketris I. S., How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?, 10.1212/01.wnl.0000271884.11129.f3
  39. Trojano Maria, Pellegrini Fabio, Fuiani Aurora, Paolicelli Damiano, Zipoli Valentina, Zimatore Giovanni B., Di Monte Elisabetta, Portaccio Emilio, Lepore Vito, Livrea Paolo, Amato Maria Pia, New natural history of interferon-β-treated relapsing multiple sclerosis, 10.1002/ana.21102
  40. Trojano Maria, Liguori Maria, Paolicelli Damiano, Zimatore Giovanni Bosco, De Robertis Francesca, Avolio Carlo, Giuliani Fabrizio, Fuiani Aurora, Livrea Paolo, , Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy, 10.1191/1352458503ms948oa
  41. Trapp Bruce D., Peterson John, Ransohoff Richard M., Rudick Richard, Mörk Sverre, Bö Lars, Axonal Transection in the Lesions of Multiple Sclerosis, 10.1056/nejm199801293380502
  42. Kuhlmann T., Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time, 10.1093/brain/awf235
  43. Lucchinetti Claudia F., Popescu Bogdan F.G., Bunyan Reem F., Moll Natalia M., Roemer Shanu F., Lassmann Hans, Brück Wolfgang, Parisi Joseph E., Scheithauer Bernd W., Giannini Caterina, Weigand Stephen D., Mandrekar Jay, Ransohoff Richard M., Inflammatory Cortical Demyelination in Early Multiple Sclerosis, 10.1056/nejmoa1100648